Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Codeine Sulfate
Overview
What is Codeine Sulfate?
Chemically, codeine is
Morphinan-6-ol,7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-(5α,6α)-, sulfate
(2:1) (salt), trihydrate. Its empirical formula is CHNO and its
molecular weight is 299.36.
Its structure is as follows:
Each tablet contains 15, 30, or 60 mg of codeine sulfate and the following
inactive ingredients: colloidal silicon dioxide, microcrystalline cellulose,
pregelatinized starch, and stearic acid.
What does Codeine Sulfate look like?
What are the available doses of Codeine Sulfate?
Each 15 mg tablet for oral administration contains 15 mg of
codeine sulfate. It is a white, biconvex tablet scored on one side, with
strength-indicating number “15” debossed on the scored side and product
identification number “54 613” debossed on the other side.
Each 30 mg tablet for oral administration contains 30 mg of codeine sulfate.
It is a white, biconvex tablet scored on one side, with strength-indicating
number “30” debossed on the scored side and product identification number “54
783” debossed on the other side.
Each 60 mg tablet for oral administration contains 60 mg of codeine sulfate.
It is a white, biconvex tablet scored on one side, with strength-indicating
number “60” debossed on the scored side and product identification number “54
412” debossed on the other side.
What should I talk to my health care provider before I take Codeine Sulfate?
Enter section text here
How should I use Codeine Sulfate?
Codeine sulfate is an opioid analgesic indicated for the relief of mild to
moderately severe pain where the use of an opioid analgesic is appropriate.
Selection of patients for treatment with codeine sulfate should
be governed by the same principles that apply to the use of similar opioid
analgesics. Physicians should individualize treatment in every case, using
non-opioid analgesics, opioids on an as needed basis and/or combination
products, and chronic opioid therapy in a progressive plan of pain
management.
As with any opioid drug product, adjust the dosing regimen for
each patient individually, taking into account the patient’s prior analgesic
treatment experience. In the selection of the initial dose of codeine sulfate,
attention should be given to the following:
• the total daily dose, potency and specific characteristics of the opioid
the patient has been taking previously;
• the reliability of the relative potency estimate used to calculate the
equivalent codeine sulfate dose needed;
• the patient’s degree of opioid tolerance;
• the general condition and medical status of the patient;
• concurrent medications;
• the type and severity of the patient’s pain;
• risk factors for abuse, addiction or diversion, including a prior history
of abuse, addiction or diversion.
The following dosing recommendations, therefore, can only be considered
suggested approaches to what is actually a series of clinical decisions over
time in the management of the pain of each individual patient.
Continual re-evaluation of the patient receiving codeine sulfate is
important, with special attention to the maintenance of pain control and the
relative incidence of side effects associated with therapy. During chronic
therapy, especially for noncancer-related pain, the continued need for the use
of opioid analgesics should be re-assessed as appropriate.
During periods of changing analgesic requirements, including initial
titration, frequent contact is recommended between physician, other members of
the healthcare team, the patient, and the caregiver/family.
The usual adult dosage for tablets is 15 mg to 60 mg repeated up
to every four hours as needed for pain. The maximum 24 hour dose is 360 mg.
The initial dose should be titrated based upon the individual patient’s
response to their initial dose of codeine. This dose can then be adjusted to an
acceptable level of analgesia taking into account the improvement in pain
intensity and the tolerability of the codeine by the patient.
It should be kept in mind, however, that tolerance to codeine sulfate can
develop with continued use and that the incidence of untoward effects is
dose-related. Adult doses of codeine higher than 60 mg fail to give commensurate
relief of pain and are associated with an appreciably increased incidence of
undesirable side effects.
When the patient no longer requires therapy with codeine sulfate,
doses should be tapered gradually to prevent signs and symptoms of withdrawal
in the physically dependent patient.
What interacts with Codeine Sulfate?
Sorry No Records found
What are the warnings of Codeine Sulfate?
Sorry No Records found
What are the precautions of Codeine Sulfate?
Sorry No Records found
What are the side effects of Codeine Sulfate?
Sorry No records found
What should I look out for while using Codeine Sulfate?
Codeine sulfate is contraindicated in patients with known
hypersensitivity to codeine or any components of the product. Persons known to
be hypersensitive to certain other opioids may exhibit cross-sensitivity to
codeine.
Codeine sulfate is contraindicated in patients with respiratory depression in
the absence of resuscitative equipment.
Codeine sulfate is contraindicated in patients with acute or severe bronchial
asthma or hypercarbia.
Codeine sulfate is contraindicated in any patient who has or is suspected of
having paralytic ileus.
What might happen if I take too much Codeine Sulfate?
Acute overdose of codeine is characterized by respiratory
depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes
respiration, cyanosis), extreme somnolence progressing to stupor or coma, miosis
(mydriasis may occur in terminal narcosis or severe hypoxia), skeletal muscle
flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In
severe overdosage, apnea, circulatory collapse, cardiac arrest, and death may
occur.
Codeine sulfate may cause miosis, even in total darkness. Pinpoint pupils are
a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of
hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis
rather than miosis may be seen with hypoxia in overdose situations.
Primary attention should be given to the re-establishment of
adequate respiratory exchange through provision of a patent airway and
institution of assisted or controlled ventilation as necessary. Supportive
measures (including oxygen and vasopressors) should be employed in the
management of circulatory shock and pulmonary edema accompanying overdose as
indicated. Cardiac arrest or arrhythmias may require cardiac massage or
defibrillation. Induction of emesis is not recommended because of the potential
for CNS depression and seizures. Activated charcoal is recommended if the
patient is awake and able to protect his/her airway. In persons who are at risk
for abrupt onset of seizures or mental status depression, activated charcoal
should be administered by medical or paramedical personnel capable of airway
management to prevent aspiration in the event of spontaneous emesis. Severe
agitation or seizures should be treated with an intravenous benzodiazepine.
The opioid antagonist naloxone hydrochloride is a specific antidote against
respiratory depression resulting from overdosage or unusual sensitivity to
opiate agonists, including codeine. Therefore, an appropriate dose of naloxone
hydrochloride (see prescribing information for naloxone hydrochloride) should be
administered, preferably by the intravenous route, simultaneously with efforts
at respiratory resuscitation. Since the duration of action of codeine may exceed
that of the antagonist, the patient should be kept under continued surveillance
and repeated doses of the antagonist should be administered as needed to
maintain adequate respiration. A narcotic antagonist should not be administered
in the absence of clinically significant respiratory or cardiovascular
depression secondary to codeine sulfate overdose.
In an individual physically dependent on opioids, administration of the usual
dose of the antagonist will precipitate an acute withdrawal syndrome. The
severity of the withdrawal symptoms experienced will depend on the degree of
physical dependence and the dose of the antagonist administered. Use of an
opioid antagonist should be reserved for cases where such treatment is clearly
needed. If it is necessary to treat serious respiratory depression in the
physically dependent patient, administration of the antagonist should be
initiated with care and titrated with smaller than usual doses.
How should I store and handle Codeine Sulfate?
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP] .Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.Codeine SulfateNDC 54868-2541-0: Bottles of 10 TabletsNDC 54868-2541-1: Bottles of 30 TabletsNDC 54868-2541-2: Bottles of 60 Tablets StorageStore at Controlled Room Temperature, 15º to 30ºC (59º to 86ºF). Protect from moisture and light. Dispense in well-closed container as defined in the USP/NF.All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Codeine sulfate is an opioid analgesic, related to morphine, but
with less potent analgesic properties. Codeine is selective for the mu receptor,
but with a much weaker affinity than morphine. The analgesic properties of
codeine have been speculated to come from its conversion to morphine, although
the exact mechanism of analgesic action remains unknown.
The principal therapeutic action of codeine sulfate is analgesia.
Although the precise mechanism of the analgesic action is unknown, specific CNS
opiate receptors and endogenous compounds with morphine-like activity have been
identified throughout the brain and spinal cord and are likely to play a role in
the expression and perception of analgesic effects. Some other CNS effects of
codeine include anxiolysis, euphoria, and feelings of relaxation. Codeine
sulfate causes respiratory depression, in part by a direct effect on the
brainstem respiratory centers. Codeine sulfate and other related opioids depress
the cough reflex by direct effect on the cough center in the medulla. Codeine
sulfate may also cause miosis.
Gastric, biliary and pancreatic secretions may be decreased by
codeine. Codeine also causes a reduction in motility and is associated with an
increase in tone in the antrum of the stomach and duodenum. Digestion of food in
the small intestine is delayed and propulsive contractions are decreased.
Propulsive peristaltic waves in the colon are decreased, while tone is increased
to the point of spasm. The end result may be constipation. Codeine can cause a
marked increase in biliary tract pressure as a result of the spasm of the
sphincter of Oddi. Codeine may also cause spasms of the sphincter of the urinary
bladder.
Codeine produces peripheral vasodilation which may result in
orthostatic hypotension and fainting. Release of histamine can occur, which may
play a role in opioid-induced hypotension. Manifestations of histamine release
and/or peripheral vasodilation may include pruritus, flushing, red eyes, and
sweating.
Opioid agonists such as codeine sulfate have been shown to have a
variety of effects on the secretion of hormones. Opioids inhibit the secretion
of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate
prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin
and glucagons in humans and other species, rats and dogs. Thyroid stimulating
hormone (TSH) has been shown to be both inhibited and stimulated by
opioids.
Codeine has been shown to have a variety of effects on components
of the immune system in and animal models.
The clinical significance of these findings is unknown.
Codeine concentrations do not correlate with brain concentration
or relief of pain.
The minimum effective concentration varies widely and is influenced by a
variety of factors, including the extent of previous opioid use, age and general
medical condition. Effective doses in tolerant patients may be significantly
higher than in opioid-naïve patients.
Codeine is absorbed from the gastrointestinal tract with maximum
plasma concentration occurring 60 minutes post administration.
When 60 mg codeine sulfate was administered 30 minutes after
ingesting a high fat/high calorie meal, there was no significant change in the
rate and extent of absorption of codeine.
Administration of 15 mg codeine sulfate every four hours for 5
days resulted in steady-state concentrations of codeine, morphine,
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) within 48
hours.
Codeine has been reported to have an apparent volume of
distribution of approximately 3-6 L/kg, indicating extensive distribution of the
drug into tissues. Codeine has low plasma protein binding with about 7-25% of
codeine bound to plasma proteins.
About 70-80% of the administered dose of codeine is metabolized
by conjugation with glucuronic acid to codeine-6-glucuronide (C6G) and via -demethylation to morphine (about 5-10%) and -demethylation to norcodeine (about 10%) respectively.
UDP-glucuronosyltransferase (UGT) 2B7 and 2B4 are the major enzymes mediating
glucurodination of codeine to C6G. Cytochrome P450 2D6 is the major enzyme
responsible for conversion of codeine to morphine and P450 3A4 is the major
enzyme mediating conversion of codeine to norcodeine. Morphine and norcodeine
are further metabolized by conjugation with glucuronic acid. The glucuronide
metabolites of morphine are morphine-3-glucuronide (M3G) and
morphine-6-glucuronide (M6G). Morphine and M6G are known to have analgesic
activity in humans. The analgesic activity of C6G in humans is unknown.
Norcodeine and M3G are generally not considered to possess analgesic properties.
Approximately 90% of the total dose of codeine is excreted
through the kidneys, of which approximately 10% is unchanged codeine. Plasma
half-lives of codeine and its metabolites have been reported to be approximately
3 hours.
Non-Clinical Toxicology
Codeine sulfate is contraindicated in patients with known hypersensitivity to codeine or any components of the product. Persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine.Codeine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment.
Codeine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia.
Codeine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus.
Drug Interactions:
Respiratory depression is the primary risk of codeine sulfate. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Codeine produces dose-related respiratory depression.
Caution should be exercised when codeine sulfate is used postoperatively, in patients with pulmonary disease or shortness of breath, or whenever ventilatory function is depressed. Opioid related respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Opioids, including codeine sulfate, should be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or pre-existing respiratory depression. In such patients, even usual therapeutic doses of codeine sulfate may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-opioid analgesics should be considered, and codeine sulfate should be employed only under careful medical supervision at the lowest effective dose in such patients. [see 10 OVERDOSAGE]
Codeine sulfate is an opioid agonist of the morphine-type and a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty.
Codeine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing codeine sulfate in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.
Misuse and abuse of codeine sulfate poses a significant risk to the abuser that could result in overdose and death. Codeine may be abused by crushing, chewing, snorting or injecting the product. [see 9 DRUG ABUSE AND DEPENDENCE]
Concerns about abuse and addiction should not prevent the proper management of pain. Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
Codeine sulfate may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression, because respiratory depression, hypotension, profound sedation, coma or death may result.
Respiratory depressant effects of opioids and their capacity to elevate cerebrospinal fluid pressure resulting from vasodilation following CO retention may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, opioids including codeine sulfate, produce adverse reactions which may obscure the clinical course of patients with head injuries.
Codeine sulfate may cause severe hypotension in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume or concurrent administration of drugs such as phenothiazines or general anesthetics. Codeine sulfate may produce orthostatic hypotension and syncope in ambulatory patients.
Codeine sulfate should be administered with caution to patients in circulatory shock, as vasodilation produced by the drug may further reduce cardiac output and blood pressure.
Codeine sulfate should not be administered to patients with gastrointestinal obstruction, especially paralytic ileus because codeine sulfate diminishes propulsive peristaltic waves in the gastrointestinal tract and may prolong the obstruction.
Chronic use of opioids, including codeine sulfate, may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder. Codeine sulfate may cause or aggravate constipation.
Administration of codeine sulfate may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Codeine sulfate should be used in caution in patients with biliary tract disease, including acute pancreatitis, as codeine sulfate may cause spasm of the sphincter of Oddi and diminish biliary and pancreatic secretions.
As with other opioids, codeine sulfate should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyrodism, Addison’s disease, prostatic hypertrophy or urethral stricture. [see 8 USE IN SPECIFIC POPULATIONS] The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.
Caution should be exercised in the administration of codeine sulfate to patients with CNS depression, acute alcoholism, and delirium tremens.
All opioids may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.
Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing.
The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups.
When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see 8 USE IN SPECIFIC POPULATIONS]
Patients should be cautioned that codeine sulfate could impair the mental and/or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
Patients should also be cautioned about the potential combined effects of codeine sulfate with other CNS depressants, including opioids, phenothiazines, sedative/hypnotics, and alcohol. [see 7 DRUG INTERACTIONS]
Serious adverse reactions associated with codeine are respiratory depression and, to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest.
The most frequently observed adverse reactions with codeine administration include drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, sweating, and constipation.
Other adverse reactions include allergic reactions, euphoria, dysphoria, abdominal pain, and pruritis.
Other less frequently observed adverse reactions expected from opioid analgesics, including codeine sulfate, include:
Cardiovascular system:
Digestive System:
Nervous system:
Skin and Appendages:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).